Pfizer bought Hospira in 2015 to strengthen its generic drugs business, and gain a strong foothold in sterile injectables and the growing biosimilar market. It is Hospira’s biosimilar pipeline that holds to the most promise as far as Pfizer’s upside potential is concerned.
from Forbes Real Time http://www.forbes.com/sites/greatspeculations/2017/07/03/why-investment-in-biosimilars-is-important-for-pfizer/
via IFTTT
No comments:
Post a Comment